Dendritic Cell as an effective cancer immuno-cell therapy module I. : Anti-tumor effect of cultured DCs in murine leukemia model

  • In, So-Hee (The Cancer Center, Samsung Medical Center, School of Medicine, Sungkyunkwan University) ;
  • Kim, Myung-Ju (Hematology/Onclology, Samsung Medical Center, School of Medicine, Sungkyungkwan Unviersity) ;
  • Baek, So-Young (Hematology/Onclology, Samsung Medical Center, School of Medicine, Sungkyungkwan Unviersity) ;
  • Lee, Hong-Gi (Hematology/Onclology, Samsung Medical Center, School of Medicine, Sungkyungkwan Unviersity) ;
  • Kim, Ki-Hyun (Hematology/Onclology, Samsung Medical Center, School of Medicine, Sungkyungkwan Unviersity) ;
  • Lee, Hyun-Ah (Hematology/Onclology, Samsung Medical Center, School of Medicine, Sungkyungkwan Unviersity)
  • Published : 2003.10.01

Abstract

As a potent antigen presenting cells and a powerful inducer of antigen specific immunity including cytotoxic T cell activity, dendritic cells(DCs) are being considered as a promising anti-tumor therapeutic module. Unlike solid tumors, leukemia is the hematologic malignancy involving immune effector cells. The expected usage of DCs in leukemia is the treatment of minimal residual disease(MRD) after the remission or stem cell transplantation. In this study, syngeneic leukemia cells were inoculated intra-venously into the mouse (WEHI-3 into the Balb/c), and the autologous tumor cell lysate pulsed DCs were injected as a therapeutic module twice in two weeks. (omitted)

Keywords